Eight weeks after starting therapy, the levels of GCF lipocalin-2 decreased significantly in LDD-treated periodontitis groups (I, II, and III), becoming non-significantly different from the clinically healthy group (VI). The gene discussed is LCN2; the disease is periodontitis.